Larimar Therapeutics, Inc. (LRMR)

Several events have impacted Larimar Therapeutics, Inc. stock price in the past six months. The FDA provided recommendations for the BLA submission for the Friedreich's Ataxia program, and the company plans to submit its BLA in Q2 2026. The company closed an underwritten public offering of common stock and reported its second-quarter 2025 financial results. Larimar Therapeutics announced positive data from its ongoing long-term open-label study. Citizens reiterated its "Market Outperform" rating, while Jones Trading lowered its price target. A lock-up agreement for certain stock ended on October 28, 2025. Analyst consensus forecasts indicate strong optimism for the stock price.

As a clinical-stage biopharmaceutical company, Larimar Therapeutics, Inc. does not have commercialized products and therefore does not experience demand seasonality. The company's value is driven by clinical trial outcomes, regulatory milestones, and financing activities.

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases, utilizing its cell penetrating peptide technology. Their lead product, CTI-1601, is in Phase 2 trials for Friedreich's Ataxia, a genetic disease caused by insufficient frataxin. The company is also exploring treatments for other mitochondrial disorders, including CTI-1501 for Duchenne muscular dystrophy. As a clinical-stage company, revenues are limited to collaborations and investments.

Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania, United States. It is advancing a global Phase 3 study for its Friedreich's Ataxia program with sites in multiple countries.

Larimar Therapeutics' brand reputation is tied to its clinical progress and regulatory interactions for CTI-1601. Positive developments include positive data from its open-label study and the FDA's openness to using skin frataxin concentrations as a surrogate endpoint. Challenges include a past clinical hold on CERE-010 due to safety concerns and Jones Trading lowering its price target in September 2025.

As of August 29, 2025, institutional ownership of Larimar Therapeutics, Inc. stood at 83.77%, while insider ownership was 1.07%.